As part of a conversation with PharmaPhorum, a prominent source for pharmaceutical industry news, trends, and policy, Dr. Michael Christman, Coriell Institute's President and CEO, details his promising outlook on the future of genome-informed healthcare.
Topics of discussion include the increasing application and accessibility of genetic information, the patient implications associated with moving to a more individualized medical model, and an examination of the impending challenges facing this emerging area of research.
Dr. Christman spoke with the outlet a year ago and was able to share many of the exciting updates that have taken place in the field of personalized medicine and at the Institute since, including the Coriell Personalized Medicine Collaborative's (CPMC) successful enrollment of 2,100 U.S. Air Force medical service personnel.
"We've also been working diligently to release multigenic health condition and drug risk reports to participants enrolled in the CPMC study, because we recognize the value of incorporating as much genetic information into a model as possible," Dr. Christman tells PharmaPhorum's Hannah Blake.
"Ultimately, we feel very strongly that the data generated by the CPMC will help us migrate to a more precise system of health management," he goes on to add.
Click here to read the entire interview.
